156 related articles for article (PubMed ID: 14961171)
1. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Sier CF; Nicoletti I; Santovito ML; Frandsen T; Aletti G; Ferrari A; Lissoni A; Giavazzi R; Blasi F; Sidenius N
Thromb Haemost; 2004 Feb; 91(2):403-11. PubMed ID: 14961171
[TBL] [Abstract][Full Text] [Related]
2. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.
Sier CF; Sidenius N; Mariani A; Aletti G; Agape V; Ferrari A; Casetta G; Stephens RW; Brünner N; Blasi F
Lab Invest; 1999 Jun; 79(6):717-22. PubMed ID: 10378514
[TBL] [Abstract][Full Text] [Related]
3. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
4. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Holst-Hansen C; Hamers MJ; Johannessen BE; Brünner N; Stephens RW
Br J Cancer; 1999 Sep; 81(2):203-11. PubMed ID: 10496343
[TBL] [Abstract][Full Text] [Related]
8. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
[TBL] [Abstract][Full Text] [Related]
9. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
10. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).
Resnati M; Pallavicini I; Daverio R; Sidenius N; Bonini P; Blasi F
J Immunol Methods; 2006 Jan; 308(1-2):192-202. PubMed ID: 16386755
[TBL] [Abstract][Full Text] [Related]
11. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
[TBL] [Abstract][Full Text] [Related]
13. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
14. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
15. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
[TBL] [Abstract][Full Text] [Related]
16. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
17. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
18. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
[TBL] [Abstract][Full Text] [Related]
19. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
20. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
